VCEL
Vericel Corporation · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +6.2% ·
share flow +1.1% ·
net new positions +5.9%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 98 | 0 | 33.10M | $1.47B | +7 | −7 |
| Q1 2026 | 101 | +5 | 32.45M | $1.04B | +9 | −4 |
| Q4 2025 | 96 | +4 | 34.49M | $1.24B | +4 | — |
| Q3 2025 | 17 | +1 | 19.50M | $613.54M | +2 | −1 |
| Q2 2025 | 13 | -2 | 17.99M | $765.41M | — | −2 |
| Q1 2025 | 12 | 0 | 5.43M | $242.28M | +1 | −1 |
| Q4 2024 | 12 | 0 | 5.41M | $297.03M | +1 | −1 |
| Q3 2024 | 11 | 0 | 2.16M | $91.36M | — | — |
| Q2 2024 | 11 | — | 1.70M | $78.09M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 7.57M | -0.1% | $238.20M | 0.0% | ▼ Trim | 2 | SEC ↗ ×14 |
| 2 | The Vanguard Group ✦ (passive) | 3.52M | -1.3% | $110.64M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passive) | 2.81M | +15.3% | $88.34M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Fidelity (FMR) ✦ | 2.02M | -18.4% | $63.50M | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 5 | Geode Capital Management ✦ (passive) | 1.22M | -2.0% | $38.24M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 6 | Morgan Stanley ✦ | 551.76K | — | $17.36M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 7 | JPMorgan Chase ✦ | 537.97K | — | $16.93M | 0.0% | n/c | 1 | SEC ↗ ×14 |
| 8 | Wellington Management ✦ | 288.16K | -13.2% | $9.07M | 0.0% | ▼ Trim | 6 | SEC ↗ ×4 |
| 9 | D. E. Shaw & Co. ✦ | 243.27K | +216.0% | $7.66M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 10 | Goldman Sachs Group ✦ | 212.86K | — | $6.70M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 11 | Citadel Advisors ✦ | 181.13K | +315.7% | $5.70M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 12 | Fisher Asset Management ✦ | 169.61K | +2.4% | $5.34M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | Millennium Management ✦ | 62.86K | New | $1.98M | 0.0% | New | 1 | SEC ↗ |
| 14 | Two Sigma Investments ✦ | 52.71K | New | $1.66M | 0.0% | New | 1 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 44.09K | +6.3% | $1.39M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 16 | Gotham Asset Management ✦ | 13.39K | -2.0% | $421,320 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 17 | GAMCO Investors ✦ | 12.89K | +34.7% | $405,806 | 0.0% | ▲ Add | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Millennium Management | $1.98M | 0.0% |
| Two Sigma Investments | $1.66M | 0.0% |
Exited
| AQR Capital Management | $561,192 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 278 holders, 55.09M shares, $1.70B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 7.00K sh · $311,710
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology